O riginally described by Harold Dvorak and colleagues at the then Beth Israel Hospital and Harvard Medical School nearly 30 years ago as a vascular permeability factor, vascular endothelial growth factor (VEGF) has been one of the most extensively studied of the cytokine growth factors. 1 This led to investigations whereby manipulations of VEGF protein and/or one of its receptors have provided many advances in our understanding of blood vessel and organ development, whereas postnatal studies have led to numerous basic discoveries into angiogenesis. However, that is not all. The ability to block VEGF ligand-mediated angiogenesis has resulted in marked improvements in our ability to treat diseases that range from many forms of cancer to previously untreatable diseases within the eye. 2 Unsuccessful efforts have been undertaken to try to use VEGF gene or protein delivery to promote the growth of collateral blood vessels, ie, therapeutic angiogenesis, to treat patients with ischemic heart and peripheral artery disease. 3, 4 Finally, we are beginning to see how VEGF may have a role in normal physiology and pathology in organs such as the kidney, in ways that still need to be fully elucidated. 5, 6 In some respects, the VEGF receptor ligand family is relatively simple. 7, 8 There are relatively few ligands, with VEGF-A encoded on chromosome 6, VEGF-B on chromosome 11, VEGF-C on chromosome 4, VEGF-D on the X chromosome, and placental growth factor on chromosome 14. Most of these different VEGF genes (isoforms) have 2 or more transcriptional splice variants that result in proteins that vary in their relative heparin affinities, receptor binding, and thus potencies. There are 3 major VEGF receptors: VEGFR1 (flt-1), VEGFR2 (flk-1 or kdr), and VEGFR3 (flt-4). However, transcriptional splice variants and proteolytically cleaved products of the full-length receptors appear to act as antiangiogenic agents, because these soluble receptors either bind ligand but do not signal, or they interact with full-length receptors at the cell membrane to block ligand-mediated receptor signaling. This spices up the mix, but still, the system is far less complex than, for example, the fibroblast growth factor system, which has many more ligands and receptors. In situations in which we have failed to be successful in developing approaches to modulate or activate VEGF for clinical gain, have we underestimated the complexity of the VEGF system? VEGFA has been classically described as having 4 main splice variants (121, 165, 189, and 206), although other splice variants have been described as present. 7 Bates and coworkers 9 are largely responsible for describing a form of the VEGF 165 , termed VEGF 165 b, that is a splice variant on which exon 8 has a 6 -amino acid difference from the typical VEGF 165 . The antiangiogenic properties of VEGF 165 b in the human cancers are established, whereby this splice variant does not activate the VEGF receptor but actually inhibits VEGF receptor 2 activation. 9, 10 In this issue of Circulation Research, Manetti et al 11 present what may well be one of the most convincing pieces of evidence to date that VEGF 165 b plays a role in inhibiting angiogenesis in areas other than cancer. For example, patients with systemic sclerosis (SSc) are known to have impaired angiogenesis-mediated wound healing. The authors analyzed skin biopsy and serum blood samples from 35 individuals with SSc and 23 age-and sex-matched control subjects. VEGF was found to be upregulated in SSc patients compared with control subjects, despite the fact that there was histological evidence of impaired angiogenesis. The remarkable finding, however, was that the increase in VEGF in the SSc patients was the result of significant increases in VEGF 165 b, not VEGF 165 . They also showed that the antibodies used to recognize VEGF 165 will also detect VEGF 165 b, and thus, investigators cannot distinguish between the splice variants unless they design their studies appropriately. Even at the mRNA level, unless primer probe sets are designed to span the terminal eighth exon of the VEGFA gene, one would not be able to distinguish the proangiogenic from the antiangiogenic form of a VEGF 165 . They proceeded to show that microvascular endothelial cells (MVECs) isolated from the skin of individuals with SSc expressed and released higher levels of VEGF 165 b than MVECs from healthy individuals. Moreover, MVECs from individuals with SSc expressed higher levels of VEGFR-2 but also showed impaired phosphorylation/activation of that critical receptor and reduced capillary morphogenesis. They further showed that recombinant VEGF 165 b, as well as conditioned media from SSc MVECs, inhibited VEGF 165 -mediated VEGFR-2 phosphorylation and capillary morphogenesis in healthy MVECs, and these antiangiogenic effects were abrogated by treatment with anti-VEGF 165 b-blocking antibodies. They demonstrated that the VEGF 165 b functioned as an antiangiogenic agent in humans in an area other than cancer.
Any study that advances our understanding of human disease should give us a warm feeling; however, a chill goes through us when we consider that Manetti et al 11 were examining a situation of impaired VEGF receptor activity and angiogenesis in the face of excess VEGF ligand. Indeed, one can easily find several recent human studies in patients with peripheral arterial disease 12, 13 or ischemic heart disease 14 that also demonstrated, or inferred that there was, impaired angiogenesis despite higher levels of VEGFA ligand. Conclusions were drawn about the potential mechanism for the VEGF resistance and the impaired angiogenesis. Although these conclusions were supported by the data presented and may indeed be correct, those and many other studies did not distinguish between VEGF 165 and VEGF 165 b and thus could not exclude the possibility that the upregulation was of an angiogenesis inhibitor such as VEGF 165 b. A similar logic applies to any study that looked for changes in VEGF after an intervention, or perhaps even gene therapies that targeted transcription of the VEGF gene. One is left to conclude that human studies designed to examine expression changes in the VEGF receptor ligand axis must now include studies looking for VEGF 165 b, and perhaps VEGF 121 b and VEGF 189 b as well. 10 Viewed in another way, the report by Manetti et al 11 raises questions about human studies for which there are few nonhuman, especially mouse, data. A report from our laboratory, for example, just a few years ago in mice with diet-induced diabetes and experimental peripheral arterial disease demonstrated impaired angiogenesis and reduced VEGF receptor signaling, despite higher levels of "VEGF" ligand. 15 We tested (although not exhaustively) for VEGF 165 b mRNA expression in muscle and could not detect it (data not published). Indeed, published data on mouse VEGF 165 b are essentially absent. Therefore, one possibility is that VEGF 165 b does not exist in mice, although it has been shown to be present in the rat. 16 It is chilling and disappointing to consider the possibility that because something does not occur in mice or cannot be manipulated within the mouse genome, its potential significance is limited. The report by Manetti et al 11 should firmly establish a role for VEGF 165 b apart from tumor angiogenesis and in conditions in humans in which we seek to understand, promote, or inhibit angiogenesis.
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